TickerFacts.

Foxo Technologies Inc. (FOXO): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$9.73M
Year ended 2025-12-31
-$223.3K
Trailing 12 months to 2026-06-30
2022-12-31: -$38.68M2023-12-31: -$20.91M2024-12-31: -$6.53M2025-12-31: -$9.73M-$9.73M
2022-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$9.73Mn/m2026-04-15, From 2025-01-01
2024-12-31-$6.53Mn/m2026-04-15, From 2024-01-01
2023-12-31-$20.91Mn/m2025-04-15, From 2023-01-01
2022-12-31-$38.68Mn/a2024-06-06, From 2022-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Foxo Technologies Inc. (FOXO)2025-12-31-$9.73Mn/m
OmniAb, Inc. (OABI)2025-12-31-$47.22Mn/m
MaxCyte, Inc. (MXCT)2025-12-31-$47.56Mn/m
bioAffinity Technologies, Inc. (BIAF)2025-12-31-$10.07Mn/m
Absci Corp (ABSI)2025-12-31-$108.58Mn/m
NRC Health (NRC)2025-12-31$30.21M-26.7%
iSpecimen Inc. (ISPC)2025-12-31-$7.25Mn/m
OneMedNet Corp (ONMD)2025-12-31-$9.60Mn/m
Charles River Laboratories International, Inc. (CRL)2025-12-27$428.47M-27.3%

Compare FOXO, OABI, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗